Free Trial

Rallybio (RLYB) Competitors

Rallybio logo
$0.70 +0.07 (+10.61%)
Closing price 03/27/2025 04:00 PM Eastern
Extended Trading
$0.70 0.00 (0.00%)
As of 03/27/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RLYB vs. BMEA, BDTX, JAGX, PLRX, VTYX, ARTV, CRBU, IFRX, ATOS, and ORMP

Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Biomea Fusion (BMEA), Black Diamond Therapeutics (BDTX), Jaguar Health (JAGX), Pliant Therapeutics (PLRX), Ventyx Biosciences (VTYX), Artiva Biotherapeutics (ARTV), Caribou Biosciences (CRBU), InflaRx (IFRX), Atossa Therapeutics (ATOS), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry.

Rallybio vs.

Biomea Fusion (NASDAQ:BMEA) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by company insiders. Comparatively, 7.4% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biomea Fusion has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.45, indicating that its stock price is 245% less volatile than the S&P 500.

Biomea Fusion presently has a consensus target price of $24.64, indicating a potential upside of 889.41%. Rallybio has a consensus target price of $9.75, indicating a potential upside of 1,282.98%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than Biomea Fusion.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomea Fusion
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
3.00
Rallybio
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Biomea Fusion received 16 more outperform votes than Rallybio when rated by MarketBeat users. However, 78.57% of users gave Rallybio an outperform vote while only 68.97% of users gave Biomea Fusion an outperform vote.

CompanyUnderperformOutperform
Biomea FusionOutperform Votes
60
68.97%
Underperform Votes
27
31.03%
RallybioOutperform Votes
44
78.57%
Underperform Votes
12
21.43%

In the previous week, Biomea Fusion had 13 more articles in the media than Rallybio. MarketBeat recorded 16 mentions for Biomea Fusion and 3 mentions for Rallybio. Rallybio's average media sentiment score of 0.97 beat Biomea Fusion's score of 0.35 indicating that Rallybio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biomea Fusion
1 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rallybio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rallybio's return on equity of -77.39% beat Biomea Fusion's return on equity.

Company Net Margins Return on Equity Return on Assets
Biomea FusionN/A -118.90% -93.66%
Rallybio N/A -77.39%-69.33%

Rallybio has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomea FusionN/AN/A-$117.25M-$4.01-0.62
Rallybio$636K46.13-$74.56M-$1.35-0.52

Summary

Rallybio beats Biomea Fusion on 9 of the 17 factors compared between the two stocks.

Remove Ads
Get Rallybio News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RLYB vs. The Competition

MetricRallybioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$29.34M$6.91B$5.64B$8.06B
Dividend YieldN/A2.73%4.56%4.02%
P/E Ratio-0.447.2023.1319.03
Price / Sales46.13226.00383.8993.17
Price / CashN/A65.6738.1634.64
Price / Book0.256.476.944.33
Net Income-$74.56M$141.90M$3.20B$247.06M
7 Day Performance0.71%-3.05%-2.32%-0.53%
1 Month Performance-4.73%-4.63%3.07%-3.74%
1 Year Performance-55.66%-8.61%11.16%1.72%

Rallybio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RLYB
Rallybio
2.5256 of 5 stars
$0.71
+10.6%
$9.75
+1,283.0%
-55.7%$29.34M$636,000.00-0.4440
BMEA
Biomea Fusion
3.1304 of 5 stars
$2.79
-2.8%
$29.18
+945.9%
-83.8%$101.11MN/A-0.7050
BDTX
Black Diamond Therapeutics
3.236 of 5 stars
$1.68
-5.6%
$14.60
+769.0%
-65.9%$100.86MN/A-1.2690High Trading Volume
JAGX
Jaguar Health
0.5858 of 5 stars
$6.04
+4.6%
N/A-95.1%$99.07M$10.48M0.0050Analyst Forecast
Short Interest ↓
News Coverage
High Trading Volume
PLRX
Pliant Therapeutics
4.3309 of 5 stars
$1.59
+2.6%
$13.31
+737.3%
-89.6%$97.37M$1.58M-0.4890Short Interest ↑
VTYX
Ventyx Biosciences
2.2295 of 5 stars
$1.36
+3.0%
$10.00
+635.3%
-78.8%$96.74MN/A-0.5830Positive News
ARTV
Artiva Biotherapeutics
N/A$3.91
-8.4%
$21.00
+437.1%
N/A$94.97M$2.60M0.0081Analyst Forecast
Analyst Revision
News Coverage
CRBU
Caribou Biosciences
3.4178 of 5 stars
$1.02
-1.9%
$10.33
+913.1%
-80.7%$94.87M$9.99M-0.62100Short Interest ↓
IFRX
InflaRx
2.4438 of 5 stars
$1.41
+10.2%
$8.00
+467.4%
-18.8%$94.66M$165,789.00-1.3160Analyst Forecast
High Trading Volume
ATOS
Atossa Therapeutics
1.4833 of 5 stars
$0.75
-0.5%
$7.00
+833.3%
-61.8%$94.35MN/A-3.418Earnings Report
Analyst Forecast
News Coverage
Gap Up
ORMP
Oramed Pharmaceuticals
1.6767 of 5 stars
$2.34
+0.4%
N/A-18.4%$94.33M$1.34M21.2710
Remove Ads

Related Companies and Tools


This page (NASDAQ:RLYB) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners